Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that ...

In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an ...

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

Milestone Pharmaceuticals (MIST) announced the U.S. Food and Drug Administration, FDA, issued a Complete Response Letter, CRL, regarding its ...

Revenue in 2023 was related to a milestone payment received from Corxel Pharmaceuticals, formerly known as Ji Xing Pharmaceuticals, under the Company’s License and Collaboration Agreement.

MONTREAL and CHARLOTTE, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and full year ended ...

Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that ...